Wikidata entity: Q3993743
C₂₆H₂₈ClNO (P274)
Quantities
| P4250 | defined daily dose | 60 |
| P2067 | mass | 405.186 |
| P3780 | active ingredient in | ... | Q29005855 (Fareston) | Fareston |
| P233 | canonical SMILES | String | CN(C)CCOC1=CC=C(C=C1)C(=C(CCCl)C2=CC=CC=C2)C3=CC=CC=C3 | ??? |
| P373 | Commons category | String | Toremifene | ??? |
| P366 | has use | ... | Q12140 (medication) | medication |
| P31 | instance of | ... | Q113145171 (type of chemical entity) | type of chemical entity |
| P2017 | isomeric SMILES | String | CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)\C2=CC=CC=C2)/C3=CC=CC=C3 | ??? |
| P8026 | LiverTox likelihood score | ... | Q83284515 (LiverTox toxicity likelihood category D) | LiverTox toxicity likelihood category D |
| P2175 | medical condition treated | ... | Q128581 (breast cancer) | breast cancer |
| P636 | route of administration | ... | Q285166 (oral administration) | oral administration |
| P769 | significant drug interaction | ... | Q7739 (arsenic trioxide) | arsenic trioxide |
| P769 | significant drug interaction | ... | Q144085 (pimozide) | pimozide |
| P769 | significant drug interaction | ... | Q118551 (clarithromycin) | clarithromycin |
| P769 | significant drug interaction | ... | Q174259 (droperidol) | droperidol |
| P769 | significant drug interaction | ... | Q179996 ((RS)-methadone) | (RS)-methadone |
| P769 | significant drug interaction | ... | Q213511 (erythromycin) | erythromycin |
| P769 | significant drug interaction | ... | Q228143 (zuclopenthixol) | zuclopenthixol |
| P769 | significant drug interaction | ... | Q409672 ((RS)-citalopram) | (RS)-citalopram |
| P769 | significant drug interaction | ... | Q410011 (ondansetron) | ondansetron |
| P769 | significant drug interaction | ... | Q424940 (moxifloxacin) | moxifloxacin |
| P769 | significant drug interaction | ... | Q425120 (disopyramide) | disopyramide |
| P769 | significant drug interaction | ... | Q425137 (fingolimod) | fingolimod |
| P769 | significant drug interaction | ... | Q425729 (ivabradine) | ivabradine |
| P769 | significant drug interaction | ... | Q410061 (amiodarone) | amiodarone |
| P769 | significant drug interaction | ... | Q413591 (sotalol) | sotalol |
| P769 | significant drug interaction | ... | Q421937 ((RS)-hydroxyzine) | (RS)-hydroxyzine |
| P769 | significant drug interaction | ... | Q251347 (haloperidol) | haloperidol |
| P769 | significant drug interaction | ... | Q407972 (chlorpromazine) | chlorpromazine |
| P769 | significant drug interaction | ... | Q408163 (anagrelide) | anagrelide |
| P769 | significant drug interaction | ... | Q408637 (dronedarone) | dronedarone |
| P769 | significant drug interaction | ... | Q7914515 (vandetanib) | vandetanib |
| P769 | significant drug interaction | ... | Q422418 ((RS)-sulpiride) | (RS)-sulpiride |
| P769 | significant drug interaction | ... | Q424238 (domperidone) | domperidone |
| P769 | significant drug interaction | ... | Q736270 (mefloquine) | mefloquine |
| P769 | significant drug interaction | ... | Q3896970 (pasireotide) | pasireotide |
| P769 | significant drug interaction | ... | Q5186964 (crizotinib) | crizotinib |
| P3364 | stereoisomer of | ... | Q27164641 ((E)-Toremifene) | (E)-Toremifene |
| P2868 | subject has role | ... | Q50430266 (hormonal antineoplastic agent) | hormonal antineoplastic agent |
| P2868 | subject has role | ... | Q50430327 (bone density conservation agents) | bone density conservation agents |
| P2868 | subject has role | ... | Q903917 (selective estrogen-receptor modulators) | selective estrogen-receptor modulators |
| P2275 | World Health Organisation international non-proprietary name | Monolingualtext | toremifene | ??? |
Why not click here or view trends?
log id: 2522499